Get in on Arrowhead Pharmaceuticals Inc’s (ARWR) buy-in window today!

With 2.1 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.83 million shares. The 52-week range on ARWR shows that it touched its highest point at $35.47 and its lowest point at $16.57 during that stretch. It currently has a 1-year price target of $41.42. Beta for the stock currently stands at 0.88.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ARWR was down-trending over the past week, with a drop of -14.12%, but this was down by -25.73% over a month. Three-month performance dropped to -34.18% while six-month performance fell -34.58%. The stock lost -57.03% in the past year, while it has lost -19.10% so far this year. A look at the trailing 12-month EPS for ARWR yields -5.15 with Next year EPS estimates of -3.74. For the next quarter, that number is -0.11. This implies an EPS growth rate of 46.57% for this year and -40.04% for next year.

Float and Shares Shorts:

At present, 125.57 million ARWR shares are outstanding with a float of 104.95 million shares on hand for trading.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ARWR since 9 analysts follow the stock currently. There are 6 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 3 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$3.31327 being high and -$5.58024 being low. For ARWR, this leads to a yearly average estimate of -$4.69743. Based on analyst estimates, the high estimate for the next quarter is -$0.29 and the low estimate is -$1.35. The average estimate for the next quarter is thus -$1.02.